An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms SHINE
- Sponsors Biogen; Ionis Pharmaceuticals
- 08 Mar 2017 Protocol amended as Planned number of patients changed from 274 to 289,participents are added from (NCT01839656) and number of arms changed from 3 to 4.
- 02 Mar 2017 Planned number of patients changed from 274 to 289.
- 02 Mar 2017 Planned End Date changed from 1 Feb 2020 to 1 Aug 2022.